Asia-Pacific Neurological Disorder Drugs Market

Asia-Pacific Neurological Disorder Drugs Market Size, Share & Trends Analysis Report by Disorder Type (Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Huntington Disease, and Others), and Forecast 2020-2026
    Update Available - Forecast 2024-2030   

Published: Nov 2020 | Report Code: OMR2022763 | Category : Pharmaceuticals | Delivery Format: /

The Asia-Pacific neurological disorder drugs market is projected to grow at a significant CAGR during the forecast period (2020-2026). The key factors driving the growth of the market include the rising geriatric population, increased prevalence of neurological disorders coupled with the development of novel drugs and technologies for drug development. In the Asia-Pacific region, economies such as China, India, and Japan have a major number of geriatric populations. For instance, Japan has the world’s oldest population, as per the Weforum 2019. The country’s almost a third of its population is over 65; there are 2.3 billion people in their 70s. This population pool serves as a major target audience for the market as this age group is at increased risk of developing neurological disorders.

Visit for Global Neurological Disorder Drugs Market Report at: https://www.omrglobal.com/industry-reports/neurological-disorder-drugs-market

The Asia-Pacific neurological disorder drugs market is segmented on the basis of disorder type into Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, Huntington disease, and others. Amongst the disorder type segment, Parkinson’s disease segment is projected to hold a lucrative share in the market. The segmental growth of the market is attributed to the increased prevalence of Parkinson’s disease among people across the globe. A broad range of drugs is used for the treatment of neurological disorders, some of which include analgesics, antihypertensive, anticholinergic, hypnotic & sedatives, and others. 

Geographically, the Asia-Pacific neurological disorder drugs market is analyzed into China, India, Japan, and the Rest of Asia-Pacific. China is estimated to grow significantly during the forecast period. Further, Cadila Healthcare Ltd., Astellas Pharma Ltd., Cipla Ltd., Sun Pharmaceuticals Industries ltd., Teva Pharmaceuticals Industries Ltd., and Takeda Pharmaceutical Co., Ltd. are some of the prominent players operating in the Asia-Pacific neurological disorder drugs market. New product launches & developments, partnerships, agreements, and acquisitions are some of the growth strategies adopted by the players in order to sustain in the highly competitive market. 

Research Methodology

The market study of the Asia-Pacific neurological disorder drugs market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market
  • Whitepapers, research-papers, and news blogs
  • Company websites and their product catalog

The report is intended for the pharmaceutical industry, drug manufacturers, hospitals & clinics, research organizations, academic institutes, non-profit organizations, government organizations, regulatory bodies, and other market participants for overall market analysis and competitive analysis. The report provides an in-depth analysis of the market size and growth opportunities. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for better business decisions.

Market Segmentation:

  1. Asia-Pacific Neurological Disorder Drugs Market Research and Analysis by Disorder Type

The Report covers:

  • Comprehensive research methodology of the Asia-Pacific Neurological Disorder Drugs market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the Asia-Pacific Neurological Disorder Drugs market.
  • Insights about market determinants which are stimulating the Asia-Pacific Neurological Disorder Drugs market.
  • Detailed and extensive market segments with regional distribution of forecast revenues.
  • Extensive profiles and recent developments of the market players. 

1. Report Summary

1.1. Research Methods and Tools

1.2. Market Breakdown

1.2.1. By Segments

2. Market Overview and Insights

2.1. Scope of the Report

2.2. Major Drug Analysis

Analgesics

Antidepressants

Sedatives & Hypnotics

Antihypertensive

Others

2.3. Analyst Insight & Current Market Trends

2.3.1. Key Findings

2.3.2. Recommendations

2.3.3. Conclusion

2.4. Rules & Regulations

3. Market Determinants

3.1. Motivators

3.2. Restraints

3.3. Opportunities

4. Market Segmentation

4.1. Asia-Pacific Neurological Disorder Drugs Market by Disorder Type

4.1.1. Alzheimer’s Disease

4.1.2. Parkinson’s Disease

4.1.3. Multiple Sclerosis

4.1.4. HuntingtonDisease

4.1.5. Others

5. Regional Analysis

5.1. China

5.2. India

5.3. Japan

5.4. Rest of Asia-Pacific

6. Company Profiles 

6.1. Alembic Pharmaceuticals Ltd.

6.1.1. Overview

6.1.2. Alembic Pharmaceuticals in Neurological Disorder Drug Landscape

6.1.3. Recent Developments

6.2. Astellas Pharma Inc.

6.3. AstraZeneca Plc

6.4. Cadila Healthcare Ltd.

6.5. Cipla Ltd.

6.6. Daiichi Sankyo Espha Co., Ltd.

6.7. Eisai Co. Ltd.

6.8. GlaxoSmithKline Plc

6.9. Novartis International AG

6.10. Otsuka Pharmaceutical Co., Ltd.

6.11. Pfizer Inc.

6.12. Rusan Pharma Ltd. 

6.13. Sun Pharmaceutical Industries Ltd.

6.14. Takeda Pharmaceutical Co., Ltd.

6.15. Teva Pharmaceutical Industries Ltd.


1. ASIA-PACIFIC NEUROLOGICAL DISORDER DRUGS MARKET RESEARCH AND ANALYSIS BY DISORDER TYPE, 2019-2026 ($ MILLION)

2. ASIA-PACIFIC ALZHEIMER’S DISEASE DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)

3. ASIA-PACIFIC PARKINSON’S DISEASE DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)

4. ASIA-PACIFIC MULTIPLE SCLEROSIS DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)

5. ASIA-PACIFIC HUNTINGTON DISEASE DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)

6. ASIA-PACIFIC OTHER NEUROLOGICAL DISORDER DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)

7. ASIA-PACIFIC NEUROLOGICAL DISORDER DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)


1. ASIA-PACIFIC NEUROLOGICAL DISORDER DRUGS MARKET SHARE BY DISORDER TYPE, 2019 VS 2026 (%)

2. ASIA-PACIFIC NEUROLOGICAL DISORDER DRUGS MARKET SHARE BY COUNTRY, 2019 VS 2026 (%)

3. CHINA NEUROLOGICAL DISORDER DRUGS MARKET SIZE, 2019-2026 ($ MILLION)

4. INDIA NEUROLOGICAL DISORDER DRUGS MARKET SIZE, 2019-2026 ($ MILLION)

5. JAPAN NEUROLOGICAL DISORDER DRUGS MARKET SIZE, 2019-2026 ($ MILLION)

6. REST OF ASIA-PACIFIC NEUROLOGICAL DISORDER DRUGS MARKET SIZE, 2019-2026 ($ MILLION)